Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Pfizer complete the integration of Seagen by the end of 2024?
Yes • 50%
No • 50%
Pfizer's official press releases and announcements
Pfizer's Chief Scientific Officer Mikael Dolsten to Step Down After 15 Years, External Search Underway
Jul 9, 2024, 11:50 AM
Pfizer announced that its Chief Scientific Officer and President of Global Research & Development, Dr. Mikael Dolsten, will step down after a more than 15-year tenure at the company. Dolsten, a key figure behind the development of Pfizer's COVID-19 vaccine, joined Pfizer in 2009 following the Wyeth acquisition, where he served as president and head of R&D. Prior to Wyeth, he held significant roles at Boehringer and AstraZeneca. Pfizer has initiated an external search for Dolsten's successor, with Dolsten remaining part of the interview team and staying through the transition. This move comes as Pfizer's C-suite undergoes multiple changes post-pandemic and amid the integration of the $43 billion Seagen merger.
View original story
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Major acquisition • 25%
Divestiture of a major division • 25%
Significant R&D pivot • 25%
No major changes • 25%
Yes • 50%
No • 50%
A biotech startup • 25%
Boehringer Ingelheim • 25%
AstraZeneca • 25%
Another major pharmaceutical company • 25%
Other • 25%
External candidate from a biotech startup • 25%
External candidate from a major pharmaceutical company • 25%
Internal candidate • 25%